EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Amy Meng  1     Chia-Hsiang Hsueh  1     Liyun Ni  1     Chohee Yun  2     Cara Nelson  2    
1 Gilead Sciences, Inc, Foster City, United States
2 Gilead Sciences, Seoul, Korea, Democratic People's Republic of

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing